Asklepios BioPharmaceutical, Inc. |
Medicine Tissue Engineering
Scaffold
Dimeric/Duplexed/Self-complementary AAV or BNP vectors contain modified genomes that overcome host-cell limitations that exists with standard AAV genomes. This technology results in faster onset of gene expression, and allows for the use of lower vector doses.